Valeant Pharmaceuticals, Eisai deal

Eisai's Eisai Inc. subsidiary granted Valeant exclusive U.S. rights to develop and commercialize Targretin bexarotene for $65 million up front, plus undisclosed milestones. As part of the deal, Eisai transferred the NDA for Targretin to Valeant, which will assume all subsequent U.S. regulatory obligations. The partners declined to disclose details. ...